A study conducted at the University of Strathclyde, in collaboration with clinicians from the Walton NHS Foundation Trust, the University of Liverpool and the Western General Hospital, has helped design a blood test that speeds up brain cancer diagnosis. This patented technology uses infrared light to produce a blood sample’s biosignature then utilizes artificial intelligence to check for any signs of cancer.
The technology, which was reported in the “Nature Communications” journal, is being commercialized by ClinSpec Diagnostics Limited.
The study was led by ClinSpec Diagnostics chief scientific officer Dr. Matthew J. Baker, who also happens to be a reader in the Department of Applied and Pure Chemistry at the University of Strathclyde. Baker stated that the researchers had determined during their study that the test was effective in the clinic. He added that detecting brain tumors in the early stages had the potential to considerably improve the survival and quality of life of patients.
ClinSpec Diagnostics Research and Development Director Dr. Holly Butler asserted that the results from the study would facilitate other studies whose objective was to gain regulatory approval for the technology they’d developed and eventually offer patients speedy access to diagnosis and treatment.
University of Edinburg’s consultant neurosurgeon and senior clinical lecturer Dr. Paul Brennan, who was also a partner in the study, explained that diagnosing brain tumors was challenging, as most symptoms were nonspecific, such as memory issues and headaches. However, he added, this new test had demonstrated that it could assist doctors in identifying which patients suffering from nonspecific symptoms should undergo urgent brain imaging, which meant a swift diagnosis for individuals with brain tumors and rapid access to treatment as well.
Patients suffering from brain cancer often present with symptoms that are nonspecific, which consumes a lot of time before a final diagnosis can be made by a physician.
For their study, the scientists conducted an analysis of samples obtained from a prospective cohort of more than 100 patients, which led to the discovery that the blood test could correctly differentiate between healthy individuals and patients suffering from brain cancer approximately 85% of the time.
The study’s findings propose that this approach may be helpful to doctors by assisting in the prioritization of patients who require brain scans in order to diagnose brain tumors. The researchers believe that this test will play a crucial role in the diagnostic process, despite not providing an absolute diagnosis. The study was financed by the Engineering and Physical Sciences Research Council (“EPSRC”) and the Scottish Enterprise High Growth Spinout Program.
This possible blood test to diagnose brain cancers isn’t the only new exciting development in the field of brain diagnostics. Other entities such as Brain Scientific Inc. (OTCQB: BRSF) have also developed novel neurology diagnostic tools that seem poised to disrupt how brain testing has been done for decades.
NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.